ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Sells $317,250.00 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $21.18 on Friday. The stock has a market cap of $5.01 billion, a PE ratio of 75.64 and a beta of 0.64. The stock has a 50-day moving average of $18.86 and a 200-day moving average of $14.83. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same period last year, the firm posted $0.01 earnings per share. As a group, sell-side analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently modified their holdings of the business. State Street Corp lifted its position in ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after acquiring an additional 4,945,063 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after buying an additional 137,989 shares in the last quarter. Assenagon Asset Management S.A. raised its position in ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in ADMA Biologics by 17.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after acquiring an additional 447,743 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.